Roland LT, Wang H, Mehta CC, et al. - In this analysis of a comprehensive insurance claims database from the US, researchers assessed the aspirin-exacerbated respiratory disease [AERD; defined as the coexistence of 3 diagnoses: asthma, nasal polyposis, and sensitivity to cyclooxygenase in-hibitors] cohort within the MarketScan database in regard to timing of diagnoses in hopes of better knowledge of AERD progression and current practices for these individuals. In total, 5,628 individuals met criteria for study inclusion. Asthma, followed by nasal polyps, followed by drug allergy was the most common sequence of diagnoses. In patients with AERD, upper and lower airway disease (ie, nasal polyps and/or asthma) is often initially recognized, while drug sensitivity presents month to years later. This delay can be due to AERD pathophysiology and progression of the disease or due to practice patterns in diagnostic testing and coding. In order to identify these patients at the early stages of their disease progression, further work is warranted.